EVP Joseph W LaPlume bought 25 CRL shares at $174.54; stock now $179.58, down 20.8% from 52-week high.
LaPlume purchased 25 shares of CHARLES RIVER LABORATORIES INTERNATIONAL, INC. at $174.54, a modest transaction representing a 0.1% increase in his 27.4K share position. The stock has risen $5.04 since the transaction date but remains -20.8% from its 52-week high of $226.77 and has declined -15.8% over the past 30 days. Notably, the company reported a negative full-year net income despite generating $1.0B in quarterly revenue with -0.8% annual growth, indicating underlying business headwinds. His prior trades at CRL (two sells in November 2023) occurred ahead of subsequent stock gains, timing those sales poorly; this small buy purchase follows a different pattern but its minuscule size (0.1% of holdings) limits its interpretive weight.